TenNor Therapeutics Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
56
- Stock Symbol
-
06872
- Share Price
-
$8.87
- (As of Friday Closing)
TenNor Therapeutics General Information
Description
Tennor Therapeutics (Suzhou) Ltd is a near-commercial stage biotechnology company. Along with its subsidiaries, the company is principally engaged in the research and development as well as commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Its two core products are: rifotenizole (TNP-2198), a NME drug candidate developed for the treatment of H. pylori infection; and rifaquinone (TNP-2092 injection, a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections.
Contact Information
Website
www.tennortherapeutics.comCorporate Office
- Room 701, Building B7, Suzhou Industrial Park
- No. 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
Corporate Office
- Room 701, Building B7, Suzhou Industrial Park
- No. 218 Xinghu Street
- Suzhou, Jiangsu 215123
- China
TenNor Therapeutics Timeline
TenNor Therapeutics Stock Performance
As of 13-Nov-2026, TenNor Therapeutics’s stock price is $8.87. Its current market cap is $464M with 52.3M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.87 | $9.06 | $7.93 - $36.60 | $464M | 52.3M | 104K | -$0.42 |
TenNor Therapeutics Financials Summary
As of 30-Jun-2026, TenNor Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,436,901 | |||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (20,976) | (19,733) | (26,444) | |
| Net Income | (19,910) | (21,310) | (20,337) | (27,116) |
| Total Assets | 111,942 | 32,449 | 18,203 | 13,550 |
| Total Debt | 9,455 | 4,095 | 7,263 | 8,382 |
TenNor Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TenNor Therapeutics Comparisons
Industry
Financing
Details
TenNor Therapeutics Competitors (21)
One of TenNor Therapeutics’s 21 competitors is Bristol-Myers Squibb, a Corporation company based in Princeton, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Ona Therapeutics | Venture Capital-Backed | Barcelona, Spain | ||||
| Merck & Co. | Corporation | Rahway, NJ |
TenNor Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
TenNor Therapeutics Patents
TenNor Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026119075-A1 | Compound and use thereof | Pending | 02-Dec-2024 | ||
| WO-2026103843-A1 | Compound and use thereof | Pending | 15-Nov-2024 | ||
| AU-2025219731-A1 | Solid dispersion of compound and use thereof | Pending | 07-Feb-2024 | ||
| WO-2025167866-A1 | Solid dispersion of compound and use thereof | Pending | 07-Feb-2024 | ||
| WO-2025157240-A1 | Use of compound for preparing drug for treating bacterial metabolism-related diseases | Pending | 26-Jan-2024 |
TenNor Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TenNor Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
TenNor Therapeutics FAQs
-
When was TenNor Therapeutics founded?
TenNor Therapeutics was founded in 2013.
-
Where is TenNor Therapeutics headquartered?
TenNor Therapeutics is headquartered in Suzhou, China.
-
What is the size of TenNor Therapeutics?
TenNor Therapeutics has 56 total employees.
-
What industry is TenNor Therapeutics in?
TenNor Therapeutics’s primary industry is Drug Discovery.
-
Is TenNor Therapeutics a private or public company?
TenNor Therapeutics is a Public company.
-
What is TenNor Therapeutics’s stock symbol?
The ticker symbol for TenNor Therapeutics is 06872.
-
What is the current stock price of TenNor Therapeutics?
As of 13-Nov-2026 the stock price of TenNor Therapeutics is $8.87.
-
What is the current market cap of TenNor Therapeutics?
The current market capitalization of TenNor Therapeutics is $464M.
-
Who are TenNor Therapeutics’s competitors?
Bristol-Myers Squibb, Gesynta Pharma, Gilead, Ona Therapeutics, and Merck & Co. are some of the 21 competitors of TenNor Therapeutics.
-
What is TenNor Therapeutics’s annual earnings per share (EPS)?
TenNor Therapeutics’s EPS for 12 months was -$0.42.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
